DOSAGE INDEX / SINGLE
Chonluten
Research, reported schedules and supply planning.
Examine Chonluten immune-cell signaling and inflammatory findings, including context-dependent responses and the limits of respiratory treatment claims.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 250–4,000 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–16 weeks
- Route / research model
- Subcutaneous
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 20 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- Chonluten is the tripeptide Glu-Asp-Gly in the original study examined here. Researchers tested it in the human-derived THP-1 monocytic cell line and in cells differentiated into macrophage-like cells. This is laboratory evidence about signaling and inflammatory responses, not a trial showing recovery from lung disease. [1]
- The 2022 paper compared five preparations. It reported changes in proliferative signaling, reduced LPS-stimulated inflammatory cytokines in differentiated cells, and reduced adhesion to activated endothelial cells. The authors also described modest TNF release under a different Chonluten condition and a greater apoptotic profile than with the other tested peptides. These details make the response more complex than a universal suppression of inflammation. [2]
- THP-1 is described in the study as a human leukemia monocytic cell line. The experiment uses cultured cells rather than volunteers. Its human origin does not make it a clinical efficacy or safety study. [1]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 10 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original 2022 study
- Full original article
- Int J Mol Sci (2022)Further reading · Listed in reference bibliography.
- Biomedicines (2025)Further reading · Listed in reference bibliography.
- CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.
- Signal Transduction and Targeted Therapy (2022)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- WHO (2021)Further reading · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Subcutaneous Drug Injection Review (PMC)Further reading · Listed in reference bibliography.
- Alzheimer’s Drug Discovery Foundation (2015)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.